How does a small clinic handle testosterone for women when no approved product exists?

You handle it the way you handle any off label prescribing: with a written protocol, a dose you can defend, a lab plan, a consent document, and a cash price that reflects what the work actually costs you. There is no FDA approved testosterone product indicated for women in the United States. That single fact is what shapes everything downstream, and once you accept it as a permanent condition rather than a temporary gap, the process becomes ordinary clinical practice rather than an exception you improvise each time.

The practice described here is a two clinician menopause clinic in a mid sized metro, roughly 900 active patients, about one in nine of whom are on testosterone at any given time. They started without a protocol and spent most of year one cleaning up problems they had created. What follows is the process they arrived at.

Why off label male formulations became the standard workaround

Intrinsa, a transdermal testosterone patch for women, went to FDA advisory review in 2004 and was not approved, with the committee citing insufficient long term cardiovascular and breast safety data. Nothing has replaced it. Australia and the United Kingdom have women specific low dose products. American clinicians do not.

So the workaround is a product formulated for hypogonadal men, used at a fraction of the dose: either a transdermal gel at roughly one tenth of a male daily dose, or a compounded cream at a stated concentration from a 503A pharmacy.

The Global Consensus Position Statement on the use of testosterone therapy for women, endorsed by a group of international menopause and endocrine societies, is the document most clinics anchor to. Its position is narrow and worth quoting to yourself before every new start: the only evidence based indication is hypoactive sexual desire dysfunction in postmenopausal women, and dosing should keep total testosterone within the premenopausal physiologic range. It does not endorse testosterone for fatigue, mood, cognition, bone, or body composition. Patients will ask for all five.

Gel versus compounded cream

The gel route is the more conservative one: a manufactured product with a known concentration, batch tested and stable. The problem is the packaging, which is designed to deliver a male dose, so the patient is dividing something never meant to be divided. Compounded cream solves the measurement problem and creates a sourcing problem, because concentration accuracy depends entirely on the pharmacy. If you go that route, ask for potency testing documentation on the specific formulation, not a general quality statement, and keep it in your files.

Keep reading: Is the menopause telehealth boom pulling patients away from independent clinics?

Dosing, dispensing, and the arithmetic patients get wrong at home

Here is the arithmetic that caused this clinic the most trouble in year one, laid out the way they now walk through it in the room.

Assume a 1% transdermal gel. One percent means 10 mg of testosterone per gram of gel. A common male daily dose is 5 g, delivering 50 mg. A tenth of that is 5 mg, which is 0.5 g of gel per day.

Now look at what the patient is holding. A 2.5 g packet contains 25 mg. To get 5 mg she needs one fifth of that packet, every day, from a foil sachet that cannot be resealed. In practice she squeezes out an amount she guesses at, uses it, and throws the rest away, or she keeps the open packet in a drawer for five days. Neither is dosing.

The metered pump is better. A pump delivering 1.25 g per actuation gives 12.5 mg of a 1% gel, and a patient told to use "half a pump" cannot halve an actuation reliably. This clinic now writes grams of product and milligrams of testosterone on the same prescription line, and has the patient demonstrate the measurement in the office before she leaves.

A worked comparison of the three routes they use:

Route	How the dose is measured	Main failure mode	Typical monthly patient cost
1% gel, packets	Fraction of an unsealable sachet	Guessing, then waste, then inconsistent serum levels	Varies widely by pharmacy and generic availability
1.62% gel, metered pump	Actuations, partial actuations unreliable	Rounding up to a full actuation, so the real dose drifts high	Varies widely by pharmacy and generic availability
Compounded cream, calibrated syringe	Marked volume in a 1 mL oral syringe	Concentration accuracy depends on the compounder	Commonly quoted as a flat cash price per two or three month supply

Those cost columns are deliberately not filled with numbers. Gel pricing swings by pharmacy, discount card, and generic supply in a way that makes any figure written today wrong by next quarter. Call two local pharmacies and your compounder, and re date the internal sheet every six months.

Controlled substance scheduling and the tracking it forces on you

Testosterone is a Schedule III controlled substance under the Anabolic Steroid Control Act. This is the operational fact most clinics underweight when they start.

What it means concretely. You need an active DEA registration in the state where you prescribe. A Schedule III prescription may be refilled up to five times within six months of issue, after which a new prescription is required, so a patient on a stable dose still cycles back to you at least twice a year regardless of clinical need. Most states now mandate electronic prescribing of controlled substances, and many require a prescription drug monitoring program check at defined intervals. If your state requires a PDMP query before an initial controlled substance prescription, that query needs to be a step in your rooming workflow, not something the clinician remembers.

Keep reading: What actually happens when a patient asks me about hormone therapy and breast cancer?

Baseline and follow up labs, and who pays for them

The protocol is short because the evidence supports a short one.

1. Baseline total testosterone before starting, drawn by liquid chromatography tandem mass spectrometry. Direct immunoassays are unreliable at the low concentrations found in women, which is the entire range you care about.
2. Recheck at three to six weeks after starting or after any dose change, timed consistently relative to application.
3. Once stable, recheck at roughly six month intervals, aligned with the visit the Schedule III refill limit already forces.

The purpose of the follow up level is not to confirm efficacy. It is to confirm you have not pushed her supraphysiologic. Symptom response and serum level correlate poorly, which is worth saying out loud to a patient who wants her dose raised because a number looked low.

Coverage is the friction point. A total testosterone in a postmenopausal woman is often billed against a diagnosis code the payer does not consider a covered indication, and the claim comes back to the patient. Quote the cash lab price at initiation, before the draw rather than after the statement.

What insurance will not cover, and how the clinic charges instead

Assume the drug is not covered. There is no approved indication for a female patient, so a plan has no formulary line to approve against. Some patients get a male product filled through their benefit without the plan noticing the sex mismatch, and some plans reject it at the pharmacy counter automatically. You cannot promise either outcome.

The clinic's response was to stop pretending the medication is the billable thing. The visit is. Evaluation and management visits for the underlying menopause encounter bill normally to the plan, and the testosterone specific work, initiation counseling, measurement teaching, interval level review, is folded into those visits rather than sold separately.

The compounded cream is paid to the partner pharmacy directly at the pharmacy's price, with no clinic markup. Marking up a controlled substance you dispense yourself pulls you into a separate regulatory conversation about in office dispensing licensure that a two clinician practice does not want to have.

See how PauseNotes handles this for menopause and midlife women's health clinics

Consent language for an off label indication

Off label prescribing is legal and common. Documenting it is what protects you. The clinic's one page consent covers six points, and every one of them earned its place after a real conversation went wrong.

• The product is approved for men and is being prescribed off label. No product is approved for women in the United States.
• The evidence supported use is low sexual desire that causes distress, after menopause. Other benefits are not established.
• Known side effects at physiologic doses include acne and unwanted hair growth at the application site or generally, usually dose responsive.
• Voice deepening and clitoral enlargement are associated with supraphysiologic dosing and may not fully reverse. This is why dose escalation is not open ended.
• Long term safety data on breast and cardiovascular outcomes are limited.
• Transfer to a partner, a child, or a pet by skin contact is real. Cover the site, wash hands, and let it dry.

What the practice changed after its first year

Four changes, in the order they mattered.

They narrowed the indication. In the first months they started testosterone for fatigue and for low mood in patients whose estradiol was already optimized, and got a run of disappointed patients and unnecessary levels. Now the conversation about desire happens first, with a validated distress question, and if the presenting problem is fatigue they work the fatigue.

They put the PDMP check and the six month refill horizon into the scheduling template, so the follow up gets booked at the initiation visit rather than triggered by a pharmacy call.

And they started tracking response as a score rather than a recollection. That was the change with the widest effect. Testosterone response is slow and partial, and a patient at week twelve genuinely cannot tell you whether she is better than she was at week zero. Neither can you, from a note that says "improved."

The practical next step

If you are prescribing testosterone off label, the weakest part of your file is almost certainly the response record. You have a defensible dose, a lab plan, and a consent form, and then a series of narrative notes that all say roughly the same thing.

PauseNotes sends your patients a structured symptom score between visits and charts it over time, so the desire and distress items you counseled on at initiation come back as a line you can look at with her at week six and week twenty four. When the question is whether to hold the dose, raise it, or stop, the answer sits in front of both of you instead of in memory. For an off label prescription under a Schedule III registration, that record is worth building deliberately.